
Moderna Stock Soars 90% After Phase 3 Cancer Vaccine Trial Success
Moderna and Merck announced that their personalized mRNA cancer vaccine achieved its primary goal in a late-stage clinical trial. The study evaluated patients with high-risk melanoma who underwent complete surgical removal of their tumors. Administered alongside Merck immunotherapy drug Keytruda, the experimental vaccine significantly prolonged recurrence-free survival compared with Keytruda...








